Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. 06:00:00 2024-02-20 pm EST 5-day change 1st Jan Change
177,000 KRW -1.61% Intraday chart for Celltrion, Inc. -5.60% -12.16%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
South Korean Shares Close Lower on Hotter-Than-Expected US Inflation Data MT
Celltrion Pursues EMA Approval for Actemra Biosimilar MT
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates CI
Celltrion Strikes Key Anti-Cancer Treatment Deals Across Europe MT
Celltrion Holdings Actively Pursuing Nasdaq Listing MT
Celltrion Seeks US Interchangeability Designation for Autoimmune Disease Biosimilar MT
Celltrion Announces Cancellation of Over 1% of Outstanding Shares MT
South Korean Shares Decline After Latest Fed Minutes Indicate Continuation of High-Interest Rates MT
South Korean shares fall for second day after US Fed minutes RE
S.Korean shares fall after Fed minutes; biopharma leads declines RE
Celltrion Group Plans $160 Million Divestment of Primary Care Business Rights in Asia-Pacific MT
S.Korean shares hit 19-month high on biopharma, e-commerce boost RE
Celltrion's Shares Climb After Merger With Affiliate DJ
Celltrion Concludes Merger with Celltrion Healthcare MT
Celltrion, Inc. completed the acquisition of a 64.46% stake in Celltrion Healthcare Co., Ltd. CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on November 9, 2023. CI
Celltrion, Inc.'s Equity Buyback announced on November 9, 2023, has closed with 1,314,286 shares, representing 0.93% for KRW 216,584.47 million. CI
S.Korean shares end slightly higher as chipmakers advance; US CPI in focus RE
Holzapfel Effective Microbes Co., Ltd. announced that it has received KRW 5.0000292 billion in funding from URI 2022 Scale Up Fund, Winvest No.21 Investment Fund, Celltrion, Inc. CI
Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Celltrion, Inc. announces an Equity Buyback for 1,314,286 shares. CI
Celltrion, Inc. authorizes a Buyback Plan. CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on October 23, 2023. CI
Celltrion's Net Income Jumps in Q3 MT
South Korean shares fall after four straight sessions of gain RE
Chart Celltrion, Inc.
More charts
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical Pharmaceutical segment is involved in the manufacturing and sale of therapeutic drugs for liver disease under the name of Godex, as well as the treatment of autoimmune diseases under the name of Remsima. The Other segment manufactures and sells other generic drugs. The Company distributes its products within the domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
177,000 KRW
Average target price
222,667 KRW
Spread / Average Target
+25.80%
Consensus
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer